Financial reports
ARS
2023 FY
Annual report to shareholders
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Mar 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
8-K
Biolase Reports Full-year 2023 Results; Expects Continued Revenue Growth In 2024
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Mar 24
8-K
Other Events
27 Feb 24
8-K
Other Events
21 Feb 24
8-K
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
15 Feb 24
8-K
Results of Operations and Financial Condition
7 Feb 24
8-K
Biolase Reports Unaudited Revenue Growth for Full Year 2023 and Provides
29 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Biolase, Inc. Announces Pricing of $1.4 Million Registered Direct
8 Dec 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
23 Apr 24
POS AM
Prospectus update (post-effective amendment)
19 Apr 24
POS AM
Prospectus update (post-effective amendment)
11 Apr 24
S-1/A
IPO registration (amended)
27 Mar 24
424B1
Prospectus with pricing info
14 Feb 24
S-1/A
IPO registration (amended)
9 Feb 24
S-1/A
IPO registration (amended)
7 Feb 24
S-1/A
IPO registration (amended)
30 Jan 24
S-8
Registration of securities for employees
24 Jan 24
S-1
IPO registration
19 Jan 24
Proxies
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
DEF 14A
Definitive proxy
21 Jun 23
PRE 14A
Preliminary proxy
6 Jun 23
DEF 14A
Definitive proxy
28 Mar 23
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
30 Mar 22
PRER14A
Preliminary revised proxy
8 Mar 22
PRE 14A
Preliminary proxy
4 Mar 22
Other
EFFECT
Notice of effectiveness
23 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
24 Jan 24
EFFECT
Notice of effectiveness
14 Sep 23
CORRESP
Correspondence with SEC
12 Sep 23
CORRESP
Correspondence with SEC
12 Sep 23
CORRESP
Correspondence with SEC
8 Sep 23
CORRESP
Correspondence with SEC
8 Sep 23
Ownership
SC 13G
S.H.N. Financial Investments Ltd.
23 Feb 24
SC 13G
Lind Global Fund II LP
21 Feb 24
SC 13G
Anson Funds Management LP
14 Feb 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
Krefta Edson Roberto
10 Oct 23
3
Initial statement of insider ownership
6 Oct 23
SC 13G
Krefta Edson Roberto
12 Sep 23
4
Kenneth P. Yale
12 Jun 23
4
Martha J. DDS, PhD Somerman
12 Jun 23